Tae Min Kim

发表

Added Value of Contrast Leakage Information over the CBV Value of DSC Perfusion MRI to Differentiate between Pseudoprogression and True Progression after Concurrent Chemoradiotherapy in Glioblastoma Patients

S. Choi, J. Won, Chul-Kee Park, 2022, Investigative Magnetic Resonance Imaging.

Predictive role of galectin-3 for immune checkpoint blockades (ICBs) in advanced or metastatic non-small cell lung cancer: a potential new marker for ICB resistance

Dong-Wan Kim, Jung Sun Kim, B. Keam, 2022, Journal of Cancer Research and Clinical Oncology.

Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type.

K. Chang, Yeon-Hee Park, Y. Bang, 2005, Blood.

Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells

J. Jeon, Dong-Wan Kim, Hyo-Jung Lee, 2015, Oncotarget.

Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for These Tumors

Y. Bang, Dong-Wan Kim, D. Heo, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.

Y. Bang, Dong-Wan Kim, D. Heo, 2004, Japanese journal of clinical oncology.

Feasibility of low-dose radiotherapy for patients with stage I/II extranodal NK-/T-cell lymphoma, nasal type achieving complete response after l-asparaginase-containing chemotherapy

Y. Jeon, I. Kim, N. Choi, 2022, Clinical and Translational Radiation Oncology.

Comparative analyses of overall survival in patients with anaplastic lymphoma kinase‐positive and matched wild‐type advanced nonsmall cell lung cancer

Y. Bang, Dong-Wan Kim, D. Heo, 2012, Cancer.

Distinct and overlapping features of nodal peripheral T-cell lymphomas exhibiting a follicular helper T-cell phenotype: a multicenter study emphasizing the clinicopathological significance of follicular helper T-cell marker expression.

Sejoon Lee, Y. Jeon, Wook Youn Kim, 2022, Human pathology.

An NMR metabolomics approach for the diagnosis of leptomeningeal carcinomatosis in lung adenocarcinoma cancer patients

S. Im, B. Keam, Se-Hoon Lee, 2015, International journal of cancer.

Predictive role of galectin-3 for immune checkpoint blockades (ICBs) in advanced or metastatic non-small cell lung cancer: a potential new marker for ICB resistance

Dong-Wan Kim, Jung Sun Kim, B. Keam, 2022, Journal of Cancer Research and Clinical Oncology.

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

T. Phillips, P. Lugtenburg, M. Hutchings, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Korean Cancer Patients’ Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate

Y. Bang, Dong-Wan Kim, D. Heo, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

Clinical outcomes of radiation-based locoregional therapy in locally advanced head and neck squamous cell carcinoma patients not responding to induction chemotherapy.

Dong-Wan Kim, D. Heo, B. Keam, 2013, Oral surgery, oral medicine, oral pathology and oral radiology.

PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma

Ju-Seog Lee, Dong-Wan Kim, D. Heo, 2016, Oncotarget.

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

N. Schmitz, G. Lenz, R. Bouabdallah, 2020, Investigational New Drugs.

Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study

Dong-Wan Kim, D. Heo, B. Keam, 2016, BMC Cancer.

Clinical outcomes after incomplete cycles of R-CHOP for diffuse large B-cell lymphoma: 10 years’ real-world experience in a single institute

Junshik Hong, D. Heo, Sung-Soo Yoon, 2023, Annals of Hematology.

Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

T. Phillips, P. Lugtenburg, M. Hutchings, 2022, Blood.

Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.

P. Lugtenburg, M. Hutchings, C. Cheah, 2023, Journal of Clinical Oncology.

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

J. Ahn, M. Ahn, Keunchil Park, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion.

Dae-Ho Lee, Jeeyun Lee, S. Monemi, 2021 .

A phase Ia/Ib study of novel anti‐ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer

Sung-Bae Kim, M. Ahn, B. Keam, 2023, International journal of cancer.

Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).

R. Motzer, K. Pittman, C. Barrios, 2015 .